Session

Eosinophilic oesophagitis: The essential

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS
BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS

DIFFERENCES BETWEEN PAEDIATRIC AND ADULT EOSINOPHILIC ESOPHAGITIS AT DIAGNOSIS: RESULTS FROM THE EOE CONNECT REGISTRY
DIFFERENCES BETWEEN PAEDIATRIC AND ADULT EOSINOPHILIC ESOPHAGITIS AT DIAGNOSIS: RESULTS FROM THE EOE CONNECT REGISTRY

THE IL-20 CYTOKINES DECREASE THE EXPRESSION OF EPITHELIAL BARRIER FILAGGRINS IN EOSINOPHILIC ESOPHAGITIS
THE IL-20 CYTOKINES DECREASE THE EXPRESSION OF EPITHELIAL BARRIER FILAGGRINS IN EOSINOPHILIC ESOPHAGITIS

THE IL-20 CYTOKINES DECREASE THE EXPRESSION OF EPITHELIAL BARRIER FILAGGRINS IN EOSINOPHILIC ESOPHAGITIS
THE IL-20 CYTOKINES DECREASE THE EXPRESSION OF EPITHELIAL BARRIER FILAGGRINS IN EOSINOPHILIC ESOPHAGITIS

Eosinophilic oesophagitis: The essential  et al.

DIFFERENCES BETWEEN PAEDIATRIC AND ADULT EOSINOPHILIC ESOPHAGITIS AT DIAGNOSIS: RESULTS FROM THE EOE CONNECT REGISTRY
DIFFERENCES BETWEEN PAEDIATRIC AND ADULT EOSINOPHILIC ESOPHAGITIS AT DIAGNOSIS: RESULTS FROM THE EOE CONNECT REGISTRY

Eosinophilic oesophagitis: The essential  et al.

BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS
BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS

Eosinophilic oesophagitis: The essential  et al.

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS
SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

Eosinophilic oesophagitis: The essential  et al.

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Eosinophilic oesophagitis: The essential  et al.

Item 1 - 10 / 10
1